Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Oral methylprednisolone is cost-effective when administered in the hospital.
When administered at home, it is more effective and less costly.
Its use is associated with millions in cost savings.
It should be widely prescribed to treat multiple sclerosis relapses.
Studies have shown that oral high-dose methylprednisolone (MP) is non-inferior to intravenous MP in treating multiple sclerosis relapses in terms of effectiveness and tolerance. In order to assist with resource allocation and decision-making, its cost-effectiveness must also be assessed. Our objective was to evaluate the cost-utility of per os high-dose MP as well as the cost-savings associated with implementing the strategy.
A cost-utility analysis at 28 days was carried out using data from the French COPOUSEP multicenter, double-blind randomized controlled non-inferiority trial and the statutory health insurance reimbursement database. Costs were calculated using a societal perspective, including both direct and indirect costs. An incremental cost-effectiveness ratio was calculated and bootstrapping methods assessed the uncertainty surrounding the results. An alternative scenario analysis in which MP was administered at home was also carried out. A budgetary impact analysis was carried at five years.
In the conditions of the trial (hospitalized patients), there was no significant difference in utilities and costs at 28 days. The incremental cost-effectiveness ratio was €15,360 per quality-adjusted life-year gained. If multiple sclerosis relapses were treated at home, oral MP would be more effective, less costly and associated with annual savings up to 25 million euros for the French healthcare system.
Oral MP is cost-effective in the treatment of multiple sclerosis relapses and associated with major savings.Le texte complet de cet article est disponible en PDF.
Keywords : Multiple Sclerosis, Methylprednisolone, Oral administration, Cost-utility analysis